News | October 31, 2025
Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
The initiative will engage adolescents and youth of India in decisions about their reproductive health
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
